본문바로가기
Language
Q
U
I
C
K

Business

SK bioscience’s effort reaches beyond the development and manufacture of its own premium vaccines
and extends to working with domestic and overseas partners to create a healthy future for mankind.

CDMO/CMO

Drawing on various vaccine manufacturing technologies and expertise,
SK bioscience collaborates with other institutions and companies
that seek to produce vaccines in vaccine development, R&D collaboration, and CMO.
Development
Development image
  • Process development
  • Up-stream, down-stream and assay developments
  • Clinical batch production
  • Scale-up study & process validation
Manufacturing
Manufacturing image
  • Up-stream and down-stream process for commercialization
  • Viral vaccine/bacterial vaccine
  • Final product (PFS, vial, oral drop, freeze-drying) & packaging
Project management
Project management image
  • Streamlined project management capability from development to commercial supply
Partnership
Partnership image
  • Clinical research and development
  • Co-development and manufacturing agreement
Viral Area image
Viral Area
  • Cell culture-based manufacturing capability from 10L to 2,000L, including single-use bioreactors.
  • ACFM for adherent culture using automatic CF40
  • Continuous ultra/high/low speed centrifugation
  • BSL2 BSL3 design including bio-kill system
  • Chromatography system & UF/DF skid
  • Approved for commercial production by WHO PQ
  • Upstream, downstream & analytical development

We are working with various global companies and foundations for global healthcare.

Pre-emption of
Manufacturing Facilities
Pre-emption of Manufacturing Facilities image

COVID-19

Extended contract of exclusive manufacturing facilities for the manufacturing of vaccine components designated by CEPI between 2020 and 2022

CDMO
CDMO - Agreement for development & supply for NVX-CoV2373 antigen components image

COVID-19

Agreement for development & supply for NVX-CoV2373 antigen components

CMO
CMO - Agreement for supply for ADZ1222 antigen components image

COVID-19

Agreement for supply for ADZ1222 antigen components